66.68
+0.15(+0.23%)
Currency In USD
| Previous Close | 66.53 |
| Open | 66.92 |
| Day High | 67.13 |
| Day Low | 66.32 |
| 52-Week High | 111.29 |
| 52-Week Low | 47.25 |
| Volume | 371,431 |
| Average Volume | 1.32M |
| Market Cap | 4.56B |
| PE | 27.67 |
| EPS | 2.41 |
| Moving Average 50 Days | 58.26 |
| Moving Average 200 Days | 71.67 |
| Change | 0.15 |
If you invested $1000 in Lantheus Holdings, Inc. (LNTH) 10 years ago, it would be worth $19,051.43 as of December 25, 2025 at a share price of $66.68. Whereas If you bought $1000 worth of Lantheus Holdings, Inc. (LNTH) shares 5 years ago, it would be worth $4,505.41 as of December 25, 2025 at a share price of $66.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lantheus to Present Florbetaben F 18 Data at CTAD 2025
GlobeNewswire Inc.
Nov 24, 2025 1:30 PM GMT
BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient out
Lantheus Announces Leadership Transition Plan
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company’s Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) --
Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
PDUFA Date Set for March 29, 2026BEDFORD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disea